News | April 14, 2009

T 4 Identified as Key Molecule Capable of Triggering Stem Cells to Repair Damaged Adult Heart

April 14, 2009 – Regenerx Biopharmaceuticals Inc. said yesterday researchers at the University of Texas Southwestern Medical Center (UTSW) in Dallas, TX, published a new paper elaborating on the regenerative effects of T 4 on heart cells and blood vessel growth after a heart attack in a rodent model.

The new findings in mice suggest that introducing T 4 systemically after a heart attack encourages new growth and repair of heart cells, according to UTSW. The research findings indicate that the molecule affects developmental gene expression as early as 24 hours after systemic injection. The researchers also stated T 4 is the first known molecule capable of organ-wide activation of embryonic coronary developmental program in the adult mammalian heart after systemic administration.

“This molecule has the potential to reprogram cells in the body to get them to do what you want them to do. Obviously, the clinical implications of this are enormous because of the potential to reverse damage inflicted on heart cells after a heart attack,” said J. Michael DiMaio, M.D., the senior author of the study and a cardiothoracic surgeon at UTSW.

The study was published April 10, online in the Journal of Molecular and Cellular Cardiology and will appear in the journal in May. The work was supported by the American Heart Association, the National Institutes of Health, and the Ted Nash Long Life Foundation. Deepak Srivastava, M.D., one of the authors of the study, is a member of RegeneRx’s Scientific Advisory Board.

“We are pleased and impressed with the work conducted at UTSW, which expands upon the original work done in Dr. Srivastava’s lab when he was at UTSW and published in the journal Nature. The fact that they found that T 4 caused new blood vessel growth and prevented the death of heart cells after injury is further confirmation of the previously reported biological activities of T 4 and its potential as a drug to treat patients with ischemic injuries to the heart,” said Dr. Allan L. Goldstein, discoverer of T 4, professor of biochemistry at The George Washington University Medical School and chief scientific advisor to RegeneRx. “Their discovery of molecular signals triggered by T 4 that are essential for the differentiation of stem cells and repair of heart tissue following a heart attack strongly support RegeneRx’s clinical efforts in human subjects focused on cardioprotection and repair of the heart after ischemic damage.”

For more information: www.regenerx.com

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init